$33M in hand, Rigontec opens an office in Cambridge and sets sights on its first immuno-oncology trial
The German startup Rigontec has nailed an additional $16.5 million in financing, doubling their Series A as the RNA upstart opens a new office in Cambridge, MA and preps for its first clinical study in the red-hot immuno-oncology arena early next year.
The biotech is a pioneer of the RIG-I pathway, looking to ramp up an immune system attack on tumor cells by sticking with a route that has been attracting attention for the role it plays in the innate immune system. And the company owes a lot to the early research of Gunter Hartmann at the University of Bonn, who studied how RIG-I works naturally in activating an attack on viral pathogens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
